<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/ownership" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>144</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0001197020</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <issuerInfo>
      <issuerCik>0001714899</issuerCik>
      <issuerName>Denali Therapeutics Inc.</issuerName>
      <secFileNumber>001-38311</secFileNumber>
      <issuerAddress>
        <com:street1>161 OYSTER POINT BLVD.</com:street1>
        <com:city>SOUTH SAN FRANCISCO</com:city>
        <com:stateOrCountry>CA</com:stateOrCountry>
        <com:zipCode>94080</com:zipCode>
      </issuerAddress>
      <issuerContactPhone>(650) 866-8548</issuerContactPhone>
      <nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>SATO VICKI L</nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>
      <relationshipsToIssuer>
        <relationshipToIssuer>Director</relationshipToIssuer>
      </relationshipsToIssuer>
    </issuerInfo>
    <securitiesInformation>
      <securitiesClassTitle>Common</securitiesClassTitle>
      <brokerOrMarketmakerDetails>
        <name>Charles Schwab &amp; Co., Inc.</name>
        <address>
          <com:street1>3000 Schwab Way</com:street1>
          <com:city>Westlake</com:city>
          <com:stateOrCountry>TX</com:stateOrCountry>
          <com:zipCode>76262</com:zipCode>
        </address>
      </brokerOrMarketmakerDetails>
      <noOfUnitsSold>1666</noOfUnitsSold>
      <aggregateMarketValue>39351.00</aggregateMarketValue>
      <noOfUnitsOutstanding>137422131</noOfUnitsOutstanding>
      <approxSaleDate>09/15/2023</approxSaleDate>
      <securitiesExchangeName>NASDAQ</securitiesExchangeName>
    </securitiesInformation>
    <securitiesToBeSold>
      <securitiesClassTitle>Common</securitiesClassTitle>
      <acquiredDate>06/02/2023</acquiredDate>
      <natureOfAcquisitionTransaction>Restricted Stock Lapse</natureOfAcquisitionTransaction>
      <nameOfPersonfromWhomAcquired>Denali Therapeutics Inc.</nameOfPersonfromWhomAcquired>
      <isGiftTransaction>N</isGiftTransaction>
      <amountOfSecuritiesAcquired>1666</amountOfSecuritiesAcquired>
      <paymentDate>06/02/2023</paymentDate>
      <natureOfPayment>Equity Compensation</natureOfPayment>
    </securitiesToBeSold>
    <nothingToReportFlagOnSecuritiesSoldInPast3Months>N</nothingToReportFlagOnSecuritiesSoldInPast3Months>
    <securitiesSoldInPast3Months>
      <sellerDetails>
        <name>VICKI L SATO</name>
        <address>
          <com:street1>161 OYSTER POINT BLVD</com:street1>
          <com:city>SOUTH SAN FRANCISCO</com:city>
          <com:stateOrCountry>CA</com:stateOrCountry>
          <com:zipCode>94080</com:zipCode>
        </address>
      </sellerDetails>
      <securitiesClassTitle>Denali Therapeutics Inc.</securitiesClassTitle>
      <saleDate>06/28/2023</saleDate>
      <amountOfSecuritiesSold>1666</amountOfSecuritiesSold>
      <grossProceeds>49712.00</grossProceeds>
    </securitiesSoldInPast3Months>
    <securitiesSoldInPast3Months>
      <sellerDetails>
        <name>VICKI L SATO</name>
        <address>
          <com:street1>161 OYSTER POINT BLVD</com:street1>
          <com:city>SOUTH SAN FRANCISCO</com:city>
          <com:stateOrCountry>CA</com:stateOrCountry>
          <com:zipCode>94080</com:zipCode>
        </address>
      </sellerDetails>
      <securitiesClassTitle>Denali Therapeutics Inc.</securitiesClassTitle>
      <saleDate>07/17/2023</saleDate>
      <amountOfSecuritiesSold>1666</amountOfSecuritiesSold>
      <grossProceeds>49309.00</grossProceeds>
    </securitiesSoldInPast3Months>
    <securitiesSoldInPast3Months>
      <sellerDetails>
        <name>VICKI L SATO</name>
        <address>
          <com:street1>161 OYSTER POINT BLVD</com:street1>
          <com:city>SOUTH SAN FRANCISCO</com:city>
          <com:stateOrCountry>CA</com:stateOrCountry>
          <com:zipCode>94080</com:zipCode>
        </address>
      </sellerDetails>
      <securitiesClassTitle>Denali Therapeutics Inc.</securitiesClassTitle>
      <saleDate>08/15/2023</saleDate>
      <amountOfSecuritiesSold>1666</amountOfSecuritiesSold>
      <grossProceeds>40477.00</grossProceeds>
    </securitiesSoldInPast3Months>
    <noticeSignature>
      <noticeDate>09/15/2023</noticeDate>
      <planAdoptionDates>
        <planAdoptionDate>03/27/2023</planAdoptionDate>
      </planAdoptionDates>
      <signature>VICKI L SATO</signature>
    </noticeSignature>
  </formData>
</edgarSubmission>
[{"type": "144", "sequence": "1", "filename": "primary_doc.xml", "secsgml_size_bytes": 4698}]
144
0001197020
XXXXXXXX
LIVE
0001714899
Denali Therapeutics Inc.
001-38311
161 OYSTER POINT BLVD.
SOUTH SAN FRANCISCO
CA
94080
(650) 866-8548
SATO VICKI L
Director
Common
Charles Schwab & Co., Inc.
3000 Schwab Way
Westlake
TX
76262
1666
39351.00
137422131
09/15/2023
NASDAQ
Common
06/02/2023
Restricted Stock Lapse
Denali Therapeutics Inc.
N
1666
06/02/2023
Equity Compensation
N
VICKI L SATO
161 OYSTER POINT BLVD
SOUTH SAN FRANCISCO
CA
94080
Denali Therapeutics Inc.
06/28/2023
1666
49712.00
VICKI L SATO
161 OYSTER POINT BLVD
SOUTH SAN FRANCISCO
CA
94080
Denali Therapeutics Inc.
07/17/2023
1666
49309.00
VICKI L SATO
161 OYSTER POINT BLVD
SOUTH SAN FRANCISCO
CA
94080
Denali Therapeutics Inc.
08/15/2023
1666
40477.00
09/15/2023
03/27/2023
VICKI L SATO